Led by researchers at NDORMS as part of the Data Analysis and Real World Interrogation Network (DARWIN EU) initiative, a new ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
WASHINGTON, DC—New data from the PARTNER 3 low-risk trial of patients with symptomatic, severe aortic stenosis show that TAVI ...
More than 80% of patients implanted with a transvenous phrenic nerve stimulation device for central sleep apnea had at least ...
One mother told Newsweek she was "terrified" of losing access to the drug her daughter relies on as a result of an FDA rejection.
Thank you, Hilla, and welcome to IceCure Medical Ltd's conference call to review the financial results as of and for the twelve months ended December 31, 2025, and provide an update on recent ...
Cleveland Clinic is rolling out WISER, short for the Women’s Integrated Sports, Exercise and Research center, a purpose-built sports medicine program focused squarely on the health, performance and ...
NEW YORK and SAN SEBASTIÁN, Spain, March 17, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results